Gliclazide modified release (Uni Diamicron®);Gliclazide à libération modifiée (Uni Diamicron®)

Revue Medicale de Liege

Volumn 58, Issue 10, 2003, Pages 641-645

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Compliance; Gliclazide; Hypoglycaemia, Pharmacokinetics; Insulin secretion; Sulphonylurea; Type 2 diabetes

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; DRUG METABOLITE; GLICLAZIDE; GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; METFORMIN; UNCLASSIFIED DRUG; UNI DIAMICRON;

DIET; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG METABOLISM; DRUG RELEASE; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYDROPHILICITY; HYPOGLYCEMIA; LIVER METABOLISM; METABOLISM; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; PATIENT COMPLIANCE; REVIEW; RISK; SUSTAINED RELEASE PREPARATION; WEIGHT REDUCTION; DELAYED RELEASE FORMULATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 0345096559     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Kahn SE.- The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia, 2003, 46, 3-19.
2. Scheen AJ, Lefèbvre PJ.- Insulin resistance vs. insulin deficiency: which comes first? The old question revisited. In: Diabetes in the New Millennium (Eds: Di Mario U., Leonetti F., Pugliese G., Sbraccia P. and Signore A.), J. Wiley & Sons, New York, 2000, 101-113.
3. Leahy JL.- Impaired β-cell function with chronic hyperglycemia: "overworked β-cell" hypothesis. Diabetes Rev, 1996, 4, 298-319.
4. Turner RC, Matthews DR, Clark A, et al.- Pathogenesis of NIDDM - a disease of deficient insulin secretion. Baillière's Clin Endocrinol Metab, 1988, 2, 327-342.
5. Polonsky KS, Sturis J, Bell GI.- Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med, 1996, 334, 777-783.
6. Gerich JE.- Is insulin resistance the principal cause of type 2 diabetes? Diab Obes Metab, 1999, 1, 257-263.
7. Turner RC, Cull CA, Frighi V, Holman RR.- Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 1999, 281, 2005-2012.
8. Scheen AJ, Lefèbvre PJ.- Le diabète non insulinodépendant: de la physiopathologie au traitement. Bull Mem Acad Roy Med Belg, 1996, 151, 395-405.
9. Scheen AJ, Paquot N.- Le diabète de type 2: approches diagnostiques, objectifs glycémiques et stratégies thérapeutiques. Rev Med Liège, 1999, 54, 659-666.
10. Scheen AJ.- Les sulfamidés hypoglycémiants, 50 ans après Loubatières. Rev Med Liège, 1996, 51, 90-93.
11. Scheen AJ, Lefèbvre PJ.- Oral antidiabetic agents. A guide to selection. Drugs, 1998, 55, 225-236.
12. United Kingdom Prospective Diabetes Study (UKPDS) Group.- Intensive blood-glucose control with sufonylureas, or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352, 837-853.
13. Campbell DB, Lavielle R, Nathan C.- The mode of action and clinical pharmacology of gliclazide: a review. Diabetes Res Clin Pract, 1991, 14, S21-S36.
14. Mc Gavin JK, Perry CM, Goa KL.- Gliclazide modified release. Drugs, 2002, 62, 1357-1364.
15. Crepaldi G, Fioretto P.- Gliclazide modified release: its place in the therapeutic armamentarium. Metabolism, 2000, 49 (Suppl 2), 21-25.
16. Scheen AJ.- Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liège, 2002, 57, 352-356.
17. Frey N, Laveille C, Paraire M, et al.- Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. Br J Clin Pharmacol, 2003, 55, 147-157.
18. Harrower A.- Gliclazide modified release: from once-daily administration to 24-hour blood glucose control. Metabolism, 2000, 49 (Suppl 2), 7-11.
19. Guillausseau PJ, Greb W.- Etude du profil glycémique nycthéméral de patients diabétiques de type 2 traités par gliclazide 30 mg à libération modifiée en prise unique. Diabetes Metab, 2001, 27, 133-137.
20. Diamicron MR Study Group, Drouin P.- Diamicron MR once daily is effective and well tolerated in type 2 diabetes. A double-blind, randomised, multinational study. J Diab Compl, 2000, 14, 185-191.
21. Schernthaner G, Di Mario U, Grimaldi A.- The European GUIDE-Study: head-to-head comparison of efficacy nd safety of two once daily sulfonylureas gliclazide MR and glimepiride in 845 Type 2 diabetic patients (abstract). Diabetologia, 2003, 46 (Suppl 2), A281.
22. Dailey G, Kim MS, Lian JF.- Patient compliance and persistence with anti-hyperglycemic therapy: evaluation of a population of type 2 diabetic paients. J Int Med Res, 2002, 30, 71-79.
23. Guillausseau PJ.- Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. A survey in general practice. Diabetes Metab, 2003, 29, 79-81.
24. Paes AHP, Bakker A, Soe-Agbie CJ.- Impact of dose frequency on patient compliance. Diabetes Care, 1997, 20, 1512-1517.